The Cambridge, Mass.-based company is running a study of the neuro-spinal scaffold, an implant that’s designed to act as a physical substrate for nerve sprouting after acute spinal cord injuries. The 13th procedure in the trial, performed at Camden, N.J.’s Cooper Neurological Institute, was announced late last month.
Brigham & Women’s, which boasts 1 of the largest neurosurgery ICUs in the U.S., is a teaching hospital for Harvard Medical School. It’s the 31st site to enlist in the Inspire trial.
“Patients who suffer spinal cord injury face limited options for treatment. I’m hopeful that spinal cord research, particularly in the area of axon regeneration, will expand the options available to these patients with devastating injuries,” site principal investigator Dr. Yi Lu said in prepared remarks.
“We are pleased to welcome Dr. Lu and the team at BWH to the Inspire study. Dr. Lu is an active clinician scientist in the field of spinal cord injury, having won the 2011 Spinal Cord Injury Award given by the [American Assn. of Neurological Surgeons/Congress of Neurological Surgeons] Section on neurotrauma and critical care,” added InVivo CEO Mark Perrin.
In March, NVIV shares rose slightly after 4th-quarter and full-year 2016 earnings mostly fell in line with the consensus on Wall Street.